Study identifier:CL-9709-401-DE
ClinicalTrials.gov identifier:NCT01147224
EudraCT identifier:N/A
CTIS identifier:N/A
Alvesco for the therapy of persistent asthma with or without allergic component
asthma
-
No
Alvesco
All
400
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Sept 2016 by AstraZeneca
AstraZeneca
-
The aim of the study is to evaluate the efficacy of Alvesco in patients with persistent asthma including or excluding allergic components over 3 months, especially in the spring season. Alvesco will be inhaled by a metered-dose inhaler. The study will provide further data on safety and tolerability of Alvesco .
Location
Location
Wien, Austria, 1010
Location
Wien, Austria, 1030
Location
Wien, Austria, 1080
Location
Wien, Austria, 1090
Location
Wien, Austria, 1100
Location
Wien, Austria, 1190
Location
Wien, Austria, 1210
Location
Wien, Austria, 1220
Arms | Assigned Interventions |
---|---|
ATEM A prospective one-arm non-interventional study with asthma patients treated with Alvesco. | Drug: Alvesco This is an observational study. Therefore, the physician decides about dosage according to individual needs. Other Name: Ciclesonide |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.